Jennifer Evans Stacey - 25 Feb 2023 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Reporting relationship: Chief Legal & Compliance Officer
Issuer ticker: GRTX
Reported as of: 25 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Feb 2023, 17:56:05 UTC
Prior SEC filing: 03 Jun 2022
Next SEC filing: 31 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Chris Degnan, Attorney-in-Fact for Jennifer Evans Stacey

Key filing fact

Jennifer Evans Stacey filed Form 4 for Galera Therapeutics, Inc. (GRTX) on 28 Feb 2023.

Key facts

This page summarizes Jennifer Evans Stacey's Form 4 filing for Galera Therapeutics, Inc. (GRTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Feb 2023, 17:56.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRTX transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023.

SEC remarks

Chief Legal & Compliance Officer